Literature DB >> 33373653

Emergence of a non vaccine-cognate enterovirus A71 genotype C1 in mainland China.

Hanri Zeng1, Lina Yi2, Xiaoli Chen3, Huiqiong Zhou1, Huanying Zheng1, Jing Lu2, Fen Yang1, Caixia Li1, Ling Fang1, Xin Zhang1, Xu Jing1, Jie Wu1, Hui Li4.   

Abstract

BACKGROUND: EV-A71 is a common causative agent of hand foot and mouth disease. In mainland China, EV-A71 subgenotype C4 has been the sole circulating genotype since 2008, and was used in the production of multiple licensed vaccines. Here, we report the first detection EV-A71 C1 strains in China.
METHODS: Full genomic sequence were obtained. The origin of the EV-A71 C1 strains were tracked down by Bayesian inferences. Recombination was analyzed using Simplot program. And the antigenicity were tested using the microneutralization test.
RESULTS: The C1-GD2019 shared high identity with the C1-like lineage recently identified in Europe and was introduced into Guangdong in 2018-2019. Close genetic relatedness between the C1-GD2019 and Europe C1-like strains were observed except for the 3D-3'UTR region. The late showed high similarity with CVA genomes. Antigenic variance was found. The C1-GD2019 could not be effectively neutralized by EV-A71 C4a neutralizing antibody positive samples.
CONCLUSION: This is the first report of EV-A71 subgenotype C1 isolated in China. It is a recombinant strain originating from C1-like strains recently identified in Europe and CVA strains. The different antigenicity between the C1 strains and C4a vaccine strains highlighted the importance on closely monitoring the EV-A71 C1 strains in China.
Copyright © 2020. Published by Elsevier Ltd.

Entities:  

Keywords:  Antigenicity variance; Enterovirus A71; Genotype C1; Recombination

Mesh:

Substances:

Year:  2020        PMID: 33373653     DOI: 10.1016/j.jinf.2020.12.020

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  7 in total

1.  Enterovirus A71 antivirals: Past, present, and future.

Authors:  Jun Wang; Yanmei Hu; Madeleine Zheng
Journal:  Acta Pharm Sin B       Date:  2021-08-20       Impact factor: 14.903

2.  Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19.

Authors:  V Spagnuolo; M Guffanti; L Galli; A Poli; P Rovere Querini; M Ripa; M Clementi; P Scarpellini; A Lazzarin; M Tresoldi; L Dagna; A Zangrillo; F Ciceri; A Castagna
Journal:  Sci Rep       Date:  2020-12-04       Impact factor: 4.379

3.  SARS-CoV-2-induced SIADH: a novel cause of hyponatremia.

Authors:  Johannes Kleybolte; Benjamin Storek; Björn Hegner
Journal:  Z Gerontol Geriatr       Date:  2021-03-01       Impact factor: 1.281

4.  How is your life? understanding the relative importance of life domains amongst older adults, and their associations with self-perceived COVID-19 impacts.

Authors:  Gang Chen; Jan Abel Olsen
Journal:  Qual Life Res       Date:  2022-01-06       Impact factor: 4.147

5.  Effectiveness of methylprednisolone therapy in patients with a high-risk common type of COVID-19 pneumonia: a retrospective cohort study.

Authors:  Lei Liu; Qiu Xi Zeng; Hang Qu; Jun Jian Li; Yan Wei Yang; Yan Wen Gong; Zhong Zhi He; Yi He Zhang; Wei Zhang; Bin Liu; Li Chun Che
Journal:  Clin Exp Med       Date:  2021-10-22       Impact factor: 5.057

6.  First evidence of enterovirus A71 and echovirus 30 in Uruguay and genetic relationship with strains circulating in the South American region.

Authors:  Andrés Lizasoain; Daiana Mir; Matías Salvo; Viviana Bortagaray; Gisela Masachessi; Adrián Farías; Nélida Rodríguez-Osorio; Silvia Nates; Matías Victoria; Rodney Colina
Journal:  PLoS One       Date:  2021-08-12       Impact factor: 3.240

7.  Cardiac injury and mortality in patients with Coronavirus disease 2019 (COVID-19): insights from a mediation analysis.

Authors:  Alberto Cipriani; Federico Capone; Filippo Donato; Leonardo Molinari; Davide Ceccato; Alois Saller; Lorenzo Previato; Raffaele Pesavento; Cristiano Sarais; Paola Fioretto; Sabino Iliceto; Dario Gregori; Angelo Avogaro; Roberto Vettor
Journal:  Intern Emerg Med       Date:  2020-09-27       Impact factor: 3.397

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.